QQQ   390.81 (+0.16%)
AAPL   189.33 (-0.56%)
MSFT   379.51 (-0.83%)
META   333.00 (-1.77%)
GOOGL   135.35 (-1.35%)
AMZN   147.01 (-0.01%)
TSLA   246.78 (+0.02%)
NVDA   481.60 (+0.71%)
NIO   7.21 (+0.00%)
BABA   74.99 (-2.28%)
AMD   124.25 (+1.84%)
T   16.32 (+0.87%)
F   10.66 (+2.80%)
MU   76.62 (+0.66%)
CGC   0.56 (+4.37%)
GE   118.91 (+0.05%)
DIS   93.06 (+0.61%)
AMC   7.25 (+8.21%)
PFE   30.06 (+1.25%)
PYPL   58.33 (-0.24%)
XOM   103.63 (-0.26%)
QQQ   390.81 (+0.16%)
AAPL   189.33 (-0.56%)
MSFT   379.51 (-0.83%)
META   333.00 (-1.77%)
GOOGL   135.35 (-1.35%)
AMZN   147.01 (-0.01%)
TSLA   246.78 (+0.02%)
NVDA   481.60 (+0.71%)
NIO   7.21 (+0.00%)
BABA   74.99 (-2.28%)
AMD   124.25 (+1.84%)
T   16.32 (+0.87%)
F   10.66 (+2.80%)
MU   76.62 (+0.66%)
CGC   0.56 (+4.37%)
GE   118.91 (+0.05%)
DIS   93.06 (+0.61%)
AMC   7.25 (+8.21%)
PFE   30.06 (+1.25%)
PYPL   58.33 (-0.24%)
XOM   103.63 (-0.26%)
QQQ   390.81 (+0.16%)
AAPL   189.33 (-0.56%)
MSFT   379.51 (-0.83%)
META   333.00 (-1.77%)
GOOGL   135.35 (-1.35%)
AMZN   147.01 (-0.01%)
TSLA   246.78 (+0.02%)
NVDA   481.60 (+0.71%)
NIO   7.21 (+0.00%)
BABA   74.99 (-2.28%)
AMD   124.25 (+1.84%)
T   16.32 (+0.87%)
F   10.66 (+2.80%)
MU   76.62 (+0.66%)
CGC   0.56 (+4.37%)
GE   118.91 (+0.05%)
DIS   93.06 (+0.61%)
AMC   7.25 (+8.21%)
PFE   30.06 (+1.25%)
PYPL   58.33 (-0.24%)
XOM   103.63 (-0.26%)
QQQ   390.81 (+0.16%)
AAPL   189.33 (-0.56%)
MSFT   379.51 (-0.83%)
META   333.00 (-1.77%)
GOOGL   135.35 (-1.35%)
AMZN   147.01 (-0.01%)
TSLA   246.78 (+0.02%)
NVDA   481.60 (+0.71%)
NIO   7.21 (+0.00%)
BABA   74.99 (-2.28%)
AMD   124.25 (+1.84%)
T   16.32 (+0.87%)
F   10.66 (+2.80%)
MU   76.62 (+0.66%)
CGC   0.56 (+4.37%)
GE   118.91 (+0.05%)
DIS   93.06 (+0.61%)
AMC   7.25 (+8.21%)
PFE   30.06 (+1.25%)
PYPL   58.33 (-0.24%)
XOM   103.63 (-0.26%)

Karuna Therapeutics Stock Price, News & Analysis (NASDAQ:KRTX)

$189.48
+4.13 (+2.23%)
(As of 02:23 PM ET)
Compare
Today's Range
$185.84
$193.57
50-Day Range
$161.01
$190.94
52-Week Range
$158.38
$245.00
Volume
116,879 shs
Average Volume
329,602 shs
Market Capitalization
$7.15 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$259.38

Karuna Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.83 Rating Score
Upside/​Downside
39.5% Upside
$259.38 Price Target
Short Interest
Bearish
5.06% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.94mentions of Karuna Therapeutics in the last 14 days
Based on 5 Articles This Week
Insider Trading
Selling Shares
$5.27 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($11.31) to ($11.25) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.27 out of 5 stars

Medical Sector

494th out of 949 stocks

Pharmaceutical Preparations Industry

231st out of 437 stocks


KRTX stock logo

About Karuna Therapeutics Stock (NASDAQ:KRTX)

Karuna Therapeutics, Inc., a clinical-stage biopharmaceutical company, creates and delivers transformative medicines for people living with psychiatric and neurological conditions. Its lead product candidate includes KarXT, an oral modulator of muscarinic receptors that is in Phase III clinical trial for the treatment of acute psychosis in patients with schizophrenia; and for the treatment of central nervous system disorders, such as negative and cognitive symptoms of schizophrenia and psychosis, as well as for the treatment of various peripheral tissues and dementia-related psychosis, including Alzheimer's disease. The company also focuses on developing other muscarinic-targeted drug candidates; and intends to develop lead candidature TRPC4/5 and KAR-2618 for the treatment of mood and anxiety disorders. Karuna Therapeutics, Inc. has a license agreement with Eli Lilly and Company, and Zai Lab (Shanghai) Co., Ltd; patent license agreement with PureTech Health LLC; and drug discovery partnership with Charles River Laboratories, as well as drug discovery collaboration with PsychoGenics, Inc. The company was formerly known as Karuna Pharmaceuticals, Inc. and changed its name to Karuna Therapeutics, Inc. in March 2019. Karuna Therapeutics, Inc. was incorporated in 2009 and is headquartered in Boston, Massachusetts.

KRTX Stock Price History

KRTX Stock News Headlines

The Only Practical Solution to the World’s Looming Energy Crisis
There’s just one problem: There are more plans for new uses of nuclear than there is uranium to fuel the plants!
Karuna Therapeutics' (KRTX) Buy Rating Reaffirmed at HC Wainwright
The Only Practical Solution to the World’s Looming Energy Crisis
There’s just one problem: There are more plans for new uses of nuclear than there is uranium to fuel the plants!
Karuna Therapeutics (NASDAQ:KRTX) Trading 5.7% Higher
Karuna's (KRTX) Q3 Loss Wider-Than-Expected, Sales Miss
Q3 2023 Karuna Therapeutics Inc Earnings Call
See More Headlines
Receive KRTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Karuna Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/02/2023
Today
11/29/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
2/22/2024

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:KRTX
Fax
N/A
Employees
210
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$259.38
High Stock Price Target
$318.00
Low Stock Price Target
$209.00
Potential Upside/Downside
+36.0%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.83
Research Coverage
12 Analysts

Profitability

Net Income
$-276,340,000.00
Net Margins
-2,795.96%
Pretax Margin
-6,661.80%

Debt

Sales & Book Value

Annual Sales
$10.64 million
Book Value
$35.05 per share

Miscellaneous

Free Float
32,747,000
Market Cap
$7.20 billion
Optionable
Not Optionable
Beta
1.14
20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Key Executives

  • Dr. Andrew Craig MillerDr. Andrew Craig Miller (Age 41)
    Co-Founder & COO
    Comp: $835.4k
  • Dr. Steven M. Paul M.D. (Age 72)
    President of Research and Development, Chief Scientific Officer & Director
    Comp: $1.32M
  • Dr. Stephen K. BrannanDr. Stephen K. Brannan (Age 67)
    Chief Medical Officer
    Comp: $751.75k
  • Mr. William Meury (Age 55)
    President, CEO & Director
  • Mr. Jason Parker Brown
    Chief Financial Officer
  • Ms. Alexis Smith
    Vice President of Corporate Affairs & Investor Relations
  • Ms. Mia Kelley J.D.
    Vice President of Legal Affairs
  • Mr. Frank Truslow
    Senior Vice President of Corporate Development
  • Mr. Jonathan Rosin
    Chief Human Resources Officer
  • Dr. Alan Breier
    Chair of Scientific Advisory Board & Chief Clinical Advisor














KRTX Stock Analysis - Frequently Asked Questions

Should I buy or sell Karuna Therapeutics stock right now?

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Karuna Therapeutics in the last year. There are currently 2 hold ratings and 10 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" KRTX shares.
View KRTX analyst ratings
or view top-rated stocks.

What is Karuna Therapeutics' stock price target for 2024?

12 Wall Street analysts have issued 1-year price targets for Karuna Therapeutics' shares. Their KRTX share price targets range from $209.00 to $318.00. On average, they expect the company's share price to reach $259.38 in the next twelve months. This suggests a possible upside of 39.5% from the stock's current price.
View analysts price targets for KRTX
or view top-rated stocks among Wall Street analysts.

How have KRTX shares performed in 2023?

Karuna Therapeutics' stock was trading at $196.50 at the start of the year. Since then, KRTX stock has decreased by 5.4% and is now trading at $185.91.
View the best growth stocks for 2023 here
.

When is Karuna Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 22nd 2024.
View our KRTX earnings forecast
.

How were Karuna Therapeutics' earnings last quarter?

Karuna Therapeutics, Inc. (NASDAQ:KRTX) released its quarterly earnings data on Thursday, November, 2nd. The company reported ($3.16) EPS for the quarter, missing analysts' consensus estimates of ($2.74) by $0.42. Karuna Therapeutics had a negative trailing twelve-month return on equity of 29.58% and a negative net margin of 2,795.96%.

What other stocks do shareholders of Karuna Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Karuna Therapeutics investors own include NVIDIA (NVDA), Micron Technology (MU), Advanced Micro Devices (AMD), AbbVie (ABBV), Pfizer (PFE), Alibaba Group (BABA), Johnson & Johnson (JNJ), AT&T (T), Target (TGT) and Walt Disney (DIS).

When did Karuna Therapeutics IPO?

(KRTX) raised $70 million in an IPO on Friday, June 28th 2019. The company issued 4,400,000 shares at a price of $15.00-$17.00 per share. Goldman Sachs, Citigroup and Wells Fargo Securities served as the underwriters for the IPO and Wedbush PacGrow was co-manager.

Who are Karuna Therapeutics' major shareholders?

Karuna Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional investors include FMR LLC (14.98%), Pivotal bioVenture Partners Investment Advisor LLC (2.11%), Rock Springs Capital Management LP (1.34%), Invesco Ltd. (0.97%), Eventide Asset Management LLC (0.90%) and Brown Advisory Inc. (0.86%). Insiders that own company stock include Andrew Craig Miller, Atul Pande, James Healy, Jeffrey M Jonas, Laurie J Olson, Laurie J Olson, Puretech Health Llc, Stephen K Brannan, Steven M Paul and Troy A Ignelzi.
View institutional ownership trends
.

How do I buy shares of Karuna Therapeutics?

Shares of KRTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:KRTX) was last updated on 11/29/2023 by MarketBeat.com Staff

My Account -